EuclidSR Partners

VIVUS, Inc. is a specialty pharmaceutical company based in Campbell, California, focused on the development and commercialization of therapeutic products for obesity, diabetes, sleep apnea, and sexual health. The company offers Qsymia, a treatment for obesity designed to assist adults with a body mass index of 30 or greater, or 27 or greater with weight-related health issues, in managing their weight alongside a reduced-calorie diet and increased physical activity. VIVUS also provides PANCREAZE, which addresses exocrine pancreatic insufficiency, and STENDRA/SPEDRA, an oral medication for erectile dysfunction. Additionally, the company is advancing its pipeline with ongoing clinical studies for Qsymia to treat conditions such as obstructive sleep apnea and diabetes, as well as VI-0106 for pulmonary arterial hypertension. VIVUS has established collaborative agreements with several pharmaceutical firms to enhance its research and development efforts. Founded in 1991, VIVUS continues to focus on innovative solutions that address significant health issues facing patients.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

SkinMedica specializes in developing and commercializing a range of skin care products aimed at improving skin appearance and addressing dermatologic conditions. The company markets both prescription and non-prescription products primarily to physicians, focusing on aesthetic applications. Notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to reduce signs of aging and enhance overall skin health. SkinMedica's prescription product, VANIQA® Cream, is uniquely FDA-approved for reducing unwanted facial hair in women. Additionally, the company offers a variety of anti-aging products, moisturizers, sun protection, cleansers, and acne treatments. Colorescience Pro, a related brand, provides dermatologist-recommended cosmetics that address specific skin concerns while offering sun protection and environmental defense, available through physician and medical spa channels.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

SkinMedica specializes in developing and commercializing a range of skin care products aimed at improving skin appearance and addressing dermatologic conditions. The company markets both prescription and non-prescription products primarily to physicians, focusing on aesthetic applications. Notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to reduce signs of aging and enhance overall skin health. SkinMedica's prescription product, VANIQA® Cream, is uniquely FDA-approved for reducing unwanted facial hair in women. Additionally, the company offers a variety of anti-aging products, moisturizers, sun protection, cleansers, and acne treatments. Colorescience Pro, a related brand, provides dermatologist-recommended cosmetics that address specific skin concerns while offering sun protection and environmental defense, available through physician and medical spa channels.

Xan3D Technologies is a semiconductor manufacturer based in Merrimack, New Hampshire, specializing in hybrid integrated circuit technology. The company focuses on producing semiconductors for the data communications, telecommunications, and computing industries. Utilizing optically integrated electronic circuit technology, Xan3D Technologies designs and manufactures optical connection products aimed at enhancing next-generation data links and optical communication applications. Their offerings include flexible networking and processing solutions tailored to meet the needs of various markets within these sectors.

iJET was the first to introduce intelligence to the travel industry, which was then primarily focused on getting people from one location to another – not on keeping them safe during their trips. iJET began offering services that protected the individual traveler in March 2001, first through travel agencies and then to corporate travel departments. September 11, 2001 changed the way corporations thought about travelers and by the end of the year, iJET was protecting employees from 20 corporations.

Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.

KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.

Xan3D Technologies is a semiconductor manufacturer based in Merrimack, New Hampshire, specializing in hybrid integrated circuit technology. The company focuses on producing semiconductors for the data communications, telecommunications, and computing industries. Utilizing optically integrated electronic circuit technology, Xan3D Technologies designs and manufactures optical connection products aimed at enhancing next-generation data links and optical communication applications. Their offerings include flexible networking and processing solutions tailored to meet the needs of various markets within these sectors.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

iJET was the first to introduce intelligence to the travel industry, which was then primarily focused on getting people from one location to another – not on keeping them safe during their trips. iJET began offering services that protected the individual traveler in March 2001, first through travel agencies and then to corporate travel departments. September 11, 2001 changed the way corporations thought about travelers and by the end of the year, iJET was protecting employees from 20 corporations.

Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.

Plateau Systems is a provider of Talent Management Systems, focusing on software-as-a-service (SaaS) solutions that enhance the development, management, and analysis of organizational talent, critical to improving workforce productivity and operating performance. Founded in 1996 and headquartered in Arlington, Virginia, Plateau Systems has established a global presence with offices across the United States, Europe, and Asia Pacific. The company introduced one of the first Learning Management Systems and has since evolved its offerings into an integrated talent management platform. Its primary product, the Plateau Talent Management Suite, encompasses various functionalities, including learning management, performance management, career and succession planning, and compensation management. Additional offerings include Plateau Talent Gateway, which merges social networking with content management, Plateau Analytics for performance monitoring, and iContent, a content management system that ensures secure online content delivery. These enterprise-class applications can be deployed independently or as a cohesive, multi-tenant SaaS solution, catering to major global organizations and government agencies.

Message Pharmaceuticals